A Penny on the Dollar
By Chris Thompson,
East Bay Express
| 01. 24. 2007
The more details emerge about Proposition 71, California's $3 billion stem-cell research project, the more it all looks like a big lie that will cost us billions of dollars more than we were told.
Forget that the California Institute for Regenerative Medicine, the nonprofit set up to disburse the funds, has been disturbingly secretive about how it intends to spend the public's money. Forget about the worries over whether grant committees will ignore scientific merit and just dole out cash to their cronies. Just look at the money for a second. Back in 2004, the initiative's supporters repeatedly promised that the public subsidy - estimated at the time as $6 billion, including interest - would be substantially offset by a fortune in royalties from treatments that would inevitably spring from such research. One week before the election, Robert Klein, the real-estate mogul who spearheaded the campaign, went on The NewsHour with Jim Lehrer and promised, "The state of California will gain new jobs, new tax revenues, and intellectual property revenues to pay back the taxpayers."
Or consider the official ballot...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...